LIAISON® XL Murex HBc IgM and LIAISON® XL Murex Control HBc IgM

FDA Premarket Approval P180045 S005

This medical device record is a pma supplement. A supplement may have changed the device description/function or indication from that approved in the original pma. Be sure to look at the original pma record for more information.

Pre-market Approval Supplement Details

Changes allowing harmonization of product qc workflows

DeviceLIAISON® XL Murex HBc IgM and LIAISON® XL Murex Control HBc IgM
Generic NameTest, Hepatitis B (b Core, Be Antigen, Be Antibody, B Core Igm)
ApplicantDiaSorin Inc.
Date Received2021-11-23
Decision Date2021-12-27
PMAP180045
SupplementS005
Product CodeLOM 
Advisory CommitteeMicrobiology
Supplement Type30-day Notice
Supplement ReasonProcess Change - Manufacturer/sterilizer/packager/supplier
Expedited ReviewNo
Combination Product No
Applicant Address DiaSorin Inc. 1951 Northwestern Avenue stillwater, MN 55082

Supplemental Filings

Supplement NumberDateSupplement Type
P180045Original Filing
S011 2022-11-10 30-day Notice
S010
S009 2022-04-05 Real-time Process
S008 2022-04-05 30-day Notice
S007 2022-02-04 Real-time Process
S006 2021-11-23 30-day Notice
S005 2021-11-23 30-day Notice
S004 2021-11-23 30-day Notice
S003
S002 2021-05-27 Real-time Process
S001

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.